Incysus Therapeutics to Present at the 2018 Bio Investor Forum
October 16, 2018 08:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Lawrence Lamb, Ph.D. Incysus Therapeutics Scientific Co-Founder to Present at 10th Annual Bioprocessing Summit
August 16, 2018 08:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc., a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of...
Incysus Therapeutics Scientific Co-Founder Lawrence Lamb, PhD to Present at 8th International Gamma-Delta T Cell Conference
June 08, 2018 08:00 ET
|
Incysus Therapeutics, Inc.
Symposium Title: “Targeting of chemotherapy-induced NKG2DL by localized repetitive γδ T cell infusions: a rational therapeutic design for elimination of minimal residual primary high grade gliomas” ...
Incysus Moves Its Corporate Domicile to Delaware
May 22, 2018 08:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, May 22, 2018 (GLOBE NEWSWIRE) -- Incysus, Ltd., a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers,...
Incysus Therapeutics’ Scientific Co-Founder Lawrence Lamb, Ph.D. and Marcela Maus, M.D., Ph.D. to Co-Chair Gene Therapy Symposium During 2018 ASGCT Meeting
May 17, 2018 08:00 ET
|
Incysus Therapeutics, Inc.
Symposium Title: “Tipping Point: Gene Therapy Entering the Market” Bruce Levine, Ph.D. to Present: “Regulatory and Technical Lessons Learned in Transfer of Gene Therapy Products from Academia to...
Incysus Announces Appointment of Joy Bessenger as Senior Vice President, Finance and Strategy
May 14, 2018 10:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, May 14, 2018 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc., a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of...
Incysus to Present at BioCentury Future Leaders Conference
March 21, 2018 08:00 ET
|
Incysus, Ltd
NEW YORK, March 21, 2018 (GLOBE NEWSWIRE) -- Incysus, Ltd., a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers,...
Incysus to Present Scientific Overview at the 2018 CAR-T Congress USA Meeting
March 20, 2018 08:00 ET
|
Incysus, Ltd
NEW YORK, March 20, 2018 (GLOBE NEWSWIRE) -- Incysus, Ltd., a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, today...
Incysus Presents Positive Data on Drug-Resistant Immunotherapy for Glioblastoma at AACR CNS Immunotherapy Conference
February 13, 2018 16:00 ET
|
Incysus, Ltd
NEW YORK, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Incysus, Ltd., a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers,...
Incysus Submits Second Investigational New Drug Application for Gamma-Delta T Cell Immunotherapy Candidate
January 09, 2018 07:30 ET
|
Incysus, Ltd
NEW YORK, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Incysus, Ltd., a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, today...